A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

NCT00417885 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped See Detailed Description for Termination Reason

Conditions

Breast Neoplasms

Interventions

DRUG: exemestane
DRUG: sunitinib malate

Sponsor

Pfizer